Skip to main content
SpringerLink
Log in

Pharmacokinetics of thymoxamine in rabbits after ophthalmic and intravenous administration

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics of thymoxamine hydrochloride were studied in rabbits by the assessment of its ocular and systemic absorption after instillation of thymoxamine hydrochloride 0.5% eye drops. Plasma levels were compared with those observed after i.v. bolus administration of thymoxamine hydrochloride at 2.5 mg/kg. Deacetylthymoxamine is the main metabolite of thymoxamine, generated by esterase hydrolysis. It was evaluated, as an indication of the parent drug, in aqueous humor and plasma by an HPLC method with fluorescence detection (detection limit = 5 ng/ml). Thymoxamine was found to permeate the cornea and to be hydrolysed very quickly, showing very good absorption with a maximum aqueous humor concentration of deacetylthymoxamine of 2329 ng/ml 15 min after eye drop instillation. The study of the systemic absorption of thymoxamine allowed the exclusion of the possibility of systemic side effects following ocular treatment. In fact, considering the detection limit of the method, the plasma levels of deacetylthymoxamine are certainly more than 100-times lower than those observed with intravenous treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Birmingham A.T., Szolcsany I.J. (1965): Competitive blockade of adrenergic-receptors and histamine receptors by thymoxamine. J. Pharm. Pharmacol., 17, 449–458.

    CAS  PubMed  Google Scholar 

  2. Foster R.W. (1966): The nature of the adrenergic receptors of the trachea of the guinea pig. J. Pharm. Pharmacol., 18, 1–12.

    CAS  PubMed  Google Scholar 

  3. Drew G.M. (1976): Effects of alpha-adrenoceptor agonists and antagonists on pre- and post-synaptically located alpha-adrenoceptors. Eur. J. Pharmacol., 36, 313–320.

    Article  CAS  PubMed  Google Scholar 

  4. Bonomi L., Tomazzoli L. (1977): Thymoxamine and intraocular pressure. Graefes Arch. Clin. Exp. Ophthalmol., 204, 95–100.

    Article  CAS  Google Scholar 

  5. Wand M., Grant W.M. (1976): Thymoxamine hydrochloride: effects on the facility of outflow and intraocular pressure. Invest. Ophthalmol., 15, 400–403.

    CAS  PubMed  Google Scholar 

  6. Mapstone R. (1970): Safe mydriasis. Br. J. Ophthalmol., 54, 690–692.

    Article  CAS  PubMed  Google Scholar 

  7. Rutkowski P.C., Fernandez J.L., Galin M.A., Halasa A.H. (1973): Alpha adrenergic blockade in the treatment of angle-closure glaucoma. Trans Am. Acad. Ophthalmol. Otolaryngol., 77, 137–142.

    Google Scholar 

  8. Feniou C., Neau B., Prat G., Cheze C., Fauran F., Roquebert J. (1980): Metabolism of thymoxamine: identification of metabolites in rat. J. Pharm. Pharmacol., 32, 104–107.

    CAS  PubMed  Google Scholar 

  9. Nielsen-Kudsk F. Jakobsen P., Magnussen I.B. (1980): Plasma induced biotransformation of thymoxamine and its kinetics. Acta Pharmacol. Toxicol., 47, 11–16.

    CAS  Google Scholar 

  10. Wollmer K.O., Liedtke B., Poisson A., Hodenberg A., Steinbrecher W. (1985): Metabolism of thymoxamine. I. Studies with14C-thymoxamine in rats. Eur. J. Drug Metab. Pharmacokinet., 10, 61–69.

    Google Scholar 

  11. Duchene P., Bernouillet C., Bromet-petit J., et al. (1988): Metabolism of14C-thymoxamine in rat and man. Xenobiotica, 8, 919–928.

    Article  Google Scholar 

  12. Marquer C., Trouvin J.H., Lacolle J.Y., Dupont Ch., Jacquot C. (1991): Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects. Eur. J. Drug Metab. Pharmacokinet., 16, 183–188.

    CAS  PubMed  Google Scholar 

  13. Von Wasilewski A. (1971): Klinisch-pharmakologischer Nachweis der Wirkung von Essigsäure — [4-(2-dimethylaminoaethoxy)-5-isopropyl-2-methyl-phenyl]-ester. HCl (Moxisylyt). Arzneimittelforschung., 21, 1183–1189.

    CAS  PubMed  Google Scholar 

  14. Gomeni R., Gomeni C. (1978): Comp. Biomed. Res. 11, 345.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Investigation in Applied Pharmacobiology (CIFA), University of Navarra, Pamplona, Spain

    I. Aldana, E. González-Peñas & D. Fos

  2. Sta. Perpetua de Mogoda, Zambon SA, Barcelona, Spain

    L. Bruseghini & A. Esteras

  3. Inpharzam Ricerche SA (Zambon Group), Taverne, Switzerland

    N. Ceppi Monti & V. Gianesello

Authors
  1. I. Aldana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. González-Peñas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Fos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Bruseghini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Esteras
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Ceppi Monti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. Gianesello
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aldana, I., González-Peñas, E., Fos, D. et al. Pharmacokinetics of thymoxamine in rabbits after ophthalmic and intravenous administration. Eur. J. Drug Metab. Pharmacokinet. 19, 79–83 (1994). https://doi.org/10.1007/BF03188827

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03188827

Keywords

Search

Navigation